Kim WJ, Crosse EI, De Neef E, Etxeberria I, Sabio EY, Wang E, Bewersdorf JP, Lin KT, Lu SX, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick JH, Lewis AM, Stanley RF, DeWolf S, Urben BM, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Chandran SS, Greenbaum BD, Klebanoff CA*, Bradley RK*, Abdel-Wahab O*. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell. 2025 Apr 21:S0092-8674(25)00399-X. doi: 10.1016/j.cell.2025.03.047. Online ahead of print. *Co-corresponding author.
Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino H, Saijo A, Du A, Grishanina NR, Woo J, Diaz A, Hervey-Jumper SL, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA*, Costello JF*, Okada H*. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature. 2025 Mar;639(8054):463-473. doi: 10.1038/s41586-024-08552-0. *Co-corresponding author. **Associated commentary.
Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, DeFeo AP, Kim J, Slipek N, Jin Z, Sumstad D, Klebanoff CA, Ladner K, Sarkari A, McIvor RS, Murray TA, Miller JS, Rao M, Jensen E, Ankeny J, Khalifa MA, Chauhan A, Spilseth B, Dixit A, Provenzano PP, Pan W, Weber D, Byrne-Steele M, Henley T, McKenna DH, Johnson MJ, Webber BR, Moriarity BS. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025 May;26(5):559-570. doi: 10.1016/S1470-2045(25)00083-X. Epub 2025 Apr 29. **Associated commentary.
Avutu V, Algazaq JN, Seier K, Desir-Camille R, Qin LX, Babatunde O, Adusumilli PS, Klebanoff CA, Kotecha RR, Shoushtari AN, Slovin S, Warner AB, Park JH, Schoenfeld AJ, O’Cearbhaill R, D’Angelo S, Seo SK. Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy. Transplant Cell Ther. 2025 Feb 22:S2666-6367(25)01051-6. doi: 10.1016/j.jtct.2025.02.017.
Ma J, Ayres CM, Brambley CA, Chandran SS, Rosales TJ, Perera WWJG, Eldaly B, Murray WT, Corcelli SA, Kovrigin EL, Klebanoff CA, Baker BM. Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity. Nat Commun. 2025 Jan 20;16(1):849. doi: 10.1038/s41467-025-56004-8.
Gormally MV, Chen MF, Noronha AM, Panageas K, Reynolds M, Kohlasch K, Novak B, Kee-Velez T, Clarke N, Eubank M, Chu C, Wilhelm C, Blouin A, Kyi C, Friedman C, Rudin CM, Kris MG, Shah R, Aggen D, D’Angelo S, Shoushtari AN, Berger MF, Bandlamudi C, Klebanoff CA, Drilon A, Schoenfeld AJ, Donoghue MTA.Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies. JAMA Oncol. 2025 Jan 1;11(1):74-76. doi: 10.1001/jamaoncol.2024.5364.
James SE, Chen S, Ng BD, Fischman JS, Jahn L, Boardman AP, Rajagopalan A, Elias HK, Massa A, Manuele D, Nichols KB, Lazrak A, Lee N, Roche AM, McFarland AG, Petrichenko A, Everett JK, Bushman FD, Fei T, Kousa AI, Lemarquis AL, DeWolf S, Peled JU, Vardhana SA, Klebanoff CA, van den Brink MRM. Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. Nat Biomed Eng. 2024 Dec;8(12):1592-1614. doi: 10.1038/s41551-024-01287-3.
Notti RQ, Yi F, Heissel S, Bush MW, Molvi Z, Das P, Molina H, Klebanoff CA, Walz T. The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex. bioRxiv [Preprint]. 2024 Sep 20:2023.08.22.554360. doi: 10.1101/2023.08.22.554360.
Lupo KB, Panjwani MK, Shahid S, Sottile R, Lawry C, Kolk G, Kontopolous T, Daniyan AF, Chandran SS, Klebanoff CA, Hsu KC.Engineered NKG2C + NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome. bioRxiv [Preprint]. 2024 Aug 1:2024.07.16.603785. doi: 10.1101/2024.07.16.603785.
Ma J, Ayres CM, Brambley CA, Chandran SS, Rosales TJ, Corcelli SA, Kovrigin EL, Klebanoff CA, Baker BM.Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity. Res Sq [Preprint]. 2024 May 29:rs.3.rs-4457195. doi: 10.21203/rs.3.rs-4457195/v1.
Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A.T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat Rev Drug Discov. 2023 Dec;22(12):996-1017. doi: 10.1038/s41573-023-00809-z.
Vos JL, Burman B, Jain S, Fitzgerald CWR, Sherman EJ, Dunn LA, Fetten JV, Michel LS, Kriplani A, Ng KK, Eng J, Tchekmedyian V, Haque S, Katabi N, Kuo F, Han CY, Nadeem Z, Yang W, Makarov V, Srivastava RM, Ostrovnaya I, Prasad M, Zuur CL, Riaz N, Pfister DG, Klebanoff CA, Chan TA, Ho AL, Morris LGT. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med. 2023 Dec;29(12):3077-3089. doi: 10.1038/s41591-023-02518-x.
Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, Saijo A, Du A, Grishanina N, Woo J, Diaz A, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H.Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens. bioRxiv [Preprint]. 2023 Oct 20:2023.10.19.563178. doi: 10.1101/2023.10.19.563178.
Ascierto PA, Avallone A, Bifulco C, Bracarda S, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, Kirchhoff T, Klebanoff CA, Lesinski GB, Monette A, Neyns B, Odunsi K, Paulos CM, Powell DJ Jr, Rezvani K, Segal BH, Singh N, Sullivan RJ, Fox BA, Puzanov I. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). J Transl Med. 2023 Jul 20;21(1):488. doi: 10.1186/s12967-023-04329-7.
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM.The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001.
Kropp KN, Klebanoff CA. Less, but better: A simplified design for T cell redirection and conditional payload delivery. Cancer Cell. 2022 Dec 12;40(12):1454-1456. doi: 10.1016/j.ccell.2022.11.012.
Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022 Dec;19(12):775-790. doi: 10.1038/s41571-022-00689-z.
Klebanoff CA. T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen. Cancer Immunol Res. 2022 Aug 3;10(8):919. doi: 10.1158/2326-6066.CIR-22-0386.
Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. J Transl Med. 2022 Jun 7;20(1):257. doi: 10.1186/s12967-022-03471-y.
Chandran SS, Ma J, Klatt MG, Dündar F, Bandlamudi C, Razavi P, Wen HY, Weigelt B, Zumbo P, Fu SN, Banks LB, Yi F, Vercher E, Etxeberria I, Bestman WD, Da Cruz Paula A, Aricescu IS, Drilon A, Betel D, Scheinberg DA, Baker BM, Klebanoff CA. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 2022 May;28(5):946-957. doi: 10.1038/s41591-022-01786-3
Chan AT, Dinsfriend W, Kim J, Yum B, Sultana R, Klebanoff CA, Plodkowski A, Perez Johnston R, Ginsberg MS, Liu J, Kim RJ, Steingart R, Weinsaft JW. Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. J Cardiovasc Magn Reson. 2021 Apr 5;23(1):42. doi: 10.1186/s12968-021-00727-2.
Yi F, Klebanoff CA. Erasing iatrogenic neoantigens from in vivo CRISPR screens. Immunity. 2021 Mar 9;54(3):406-408. doi: 10.1016/j.immuni.2021.02.017.
Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, Danila DC, Doman TN, Durack JC, Fox JJ, Gluskin JS, Hoffman DM, Kang S, Kang P, Landa J, McAndrew PF, Modi S, Morris MJ, Novosiadly R, Rathkopf DE, Sanford R, Chapman SC, Tate CM, Yu D, Wong P, McArthur HL. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clin Cancer Res. 2020 Nov 1;26(21):5609-5620. doi: 10.1158/1078-0432.CCR-20-0855.
Drakes DJ, Rafiq S, Purdon TJ, Lopez AV, Chandran SS, Klebanoff CA, Brentjens RJ. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy. Cancer Immunol Res. 2020 Jun;8(6):743-755. doi: 10.1158/2326-6066.CIR-19-0910.
Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunol Res. 2020 May;8(5):672-684. doi: 10.1158/2326-6066.CIR-19-0745.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398.
Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019 Jul;290(1):127-147. doi: 10.1111/imr.12772.
Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y.
Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. 2019 Mar 29;363(6434):eaau0135. doi: 10.1126/science.aau0135.
Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722.
Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491.
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D’Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8.
Deipolyi AR, Riedl CC, Bromberg J, Chandarlapaty S, Klebanoff CA, Sofocleous CT, Yarmohammadi H, Brody LA, Boas FE, Ziv E. Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. J Vasc Interv Radiol. 2018 Sep;29(9):1226-1235. doi: 10.1016/j.jvir.2018.04.018.
Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z.
Yi F, Frazzette N, Cruz AC, Klebanoff CA, Siegel RM. Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy. Trends Mol Med. 2018 Jul;24(7):642-653. doi: 10.1016/j.molmed.2018.05.004.
Henning AN, Klebanoff CA, Restifo NP. Silencing stemness in T cell differentiation. Science. 2018 Jan 12;359(6372):163-164. doi: 10.1126/science.aar5541.
Klebanoff CA, Wolchok JD. Shared cancer neoantigens: Making private matters public. J Exp Med. 2018 Jan 2;215(1):5-7. doi: 10.1084/jem.20172188.
Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2017 Dec 7;2(23):e95103. doi: 10.1172/jci.insight.95103.
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10;35(29):3322-3329. doi: 10.1200/JCO.2017.74.5463.
Williams CM, Schonnesen AA, Zhang SQ, Ma KY, He C, Yamamoto T, Eckhardt SG, Klebanoff CA, Jiang N.Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells. Front Immunol. 2017 Jul 28;8:894. doi: 10.3389/fimmu.2017.00894.
Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017 Jun;18(6):792-802. doi: 10.1016/S1470-2045(17)30251-6.
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024.
Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.
Gejman, R, Klatt, M, Chang, A, Jones, H, Oh, C, Chandran, S, Korontsvit, T, Zakahleva, V, Dao, T, Klebanoff, CA, Schienberg, D. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research, accepted manuscript in press 2020.
Chandran, S. and Klebanoff, C.A. T cell receptor-based adoptive cancer immunotherapy: emerging efficacy and pathways of resistance. Immunological Reviews, Jul; 290(1): 127-147 2019. *Cover article.
Scott, A.C., Dunbar, F., Zumbo, P., Chandran, S.S., Klebanoff, C.A., Trivedi, P., Shakiba, M., Menocal, L., Appleby, H., Camara, S.J., Zamarin, D., Walther, T., Snyder, A.C., Femia, M.R., Comen, E.A., Wen, H.Y., Hellmann, M.D., Lauer, L., Levy, O., Glickman, M., Kaye, J., Betel, D., Philip, M., Schietinger, A. Thymocyte selection-associated HMG box protein TOX is 1 required for survival of antigen-specific T cells in tumours. Nature, Jul;571(7764):270-274, 2019.
S.K. Vodnala, R. Eil, R.J. Kishton, M. Sukumar, T.N. Yamamoto, N-H Ha, P-H Lee, M.H. Shin, S J. Patel1, Z. Yu, D.C. Palmer, M. J. Kruhlak, X. Liu, J.W. Locasale, J. Huang, R. Roychoudhuri, T. Finkel, C.A. Klebanoff, N.P. Restifo. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. Mar 29;363(6434), 2019. *Cover article, accompanying commentary.
Yamamoto, T.N, Ping-Hsien Lee, P-H, Vodnala, S.K., Devikala, G., Kishton, R.J., Yu, Z, Arash Eidizadeh, A., Eil, R.L., Fioravanti, J., Gattinoni, L., Kochenderfer, J.N., Fry, T.J., Aksoy, B.A., Hammerbacher, J.E., Cruz, A.C., Siegel, R.M., Restifo, N.P., Klebanoff, C.A. T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy. Journal of Clinical Investigation. Feb 25;129(4):1551-1565, 2019. *Accompanying commentary.